Skip to Main Content

Paper Details

BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.
Clin Cancer Res
29
2022
Author NameAffiliation
Andrew V KossenkovThe Wistar Institute
  • 1 - 1

Datasets

Release 1.2